X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want...   Read More

Making medicines more affordable: Making insurance work like insurance

By Emilie Signora  |    December 8, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

3 things to know about the importance of post-approval research and development

By Andrew Powaleny  |    December 6, 2021
Despite tremendous progress and knowledge gained from post-approval R&D, some in Congress still fail to recognize innovation doesn’t stop at U.S. Food and Drug Administration (FDA) approval. After...   Read More

Guest post: Congress should not put future innovation at risk

By Guest Contributor  |    November 29, 2021
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...   Read More

What is missing in the current drug pricing plan

By Brian Newell  |    November 23, 2021
A recent congressional forum looked at the role pharmacy benefit managers (PBMs) play in determining what patients pay out of pocket for prescription medicines. The forum provided an important...   Read More

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

By Andrew Powaleny  |    November 19, 2021
As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug...   Read More

Three things to know about so-called Medicare negotiation polling

By Tom Wilbur  |    November 18, 2021
As policymakers continue to push partisan drug pricing proposals, several polls misrepresenting voter opinion have been circulated to try and justify these flawed policies. These polls fail to...   Read More

In the current health care debate, Congress has lost sight of what matters to U.S. voters

By Debra DeShong  |    November 15, 2021
For months Congress has been debating massive changes to the nation’s social safety net, one of which is the highly popular Medicare prescription drug benefit. Unfortunately, much of what is being...   Read More

Making medicines more affordable: Modernizing Medicare

By Emilie Signora  |    November 11, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates